Karyopharm Q2 revenue falls as license revenue drops; expects funds to last into September

Karyopharm Therapeutics

13/08/2026 12:41

Overview
Cancer drug developer's Q2 revenue declined yr/yr as license and other revenue fell
U.S. XPOVIO net product revenue rose slightly to $30.8 mln
Company reaffirmed 2026 total revenue guidance and highlighted progress on myelofibrosis sNDA

Outlook
Company reaffirms 2026 total revenue guidance of $130 mln to $150 mln
Karyopharm expects 2026 U.S. XPOVIO net product revenue of $115 mln to $130 mln
Company expects existing liquidity to fund operations into September 2026

Result Drivers
STEADY XPOVIO DEMAND - Co said U.S. XPOVIO net product revenue was stable in Q2 2026 despite increased competition in multiple myeloma
ROYALTY REVENUE GROWTH - Co said expanded global patient access for selinexor led to higher royalty revenue from international partners
LICENSE REVENUE DECLINE - Co attributed lower license and other revenue to expiration of Menarini's annual R&D obligation

Company press release: ID:nPn30ytTPa

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Product Revenue
 
$30.78 mln
 
Q2 Net Loss
 
$67.02 mln
 
Q2 Operating Expenses
 
$55.96 mln
 
Q2 Operating Income
 
-$22.53 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Karyopharm Therapeutics Inc. is $7.00, about 244.8% above its August 12 closing price of $2.03

Reuters Recommended Reads
Aug 12 - Kura Oncology Q2 product revenue rises 57% on KOMZIFTI uptake
Aug 12 - Omeros Q2 YARTEMLEA net revenue jumps 190%
Aug 11 - TherapeuticsMD Q2 license revenue falls; continues to evaluate strategic alternatives

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)